1 Global leading PI
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
(OPT-822-001) All Meta 1st line & 2nd line
2 Global leading PI
A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2‑positive Early Breast Cancer
(EGC002) HER2+ neoadjuvant
3 Steering Committee
TRIO033: A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEE011]: (NATALEE) HER2-adjuvant
4 Steering Committee
KBCRN-B003/OOTR-N016: A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in Women with Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
ER+/HER2-neoadjuvant
5 Steering Committee
A Phase III, Randomized, Double-blind, Placebo Controlled Study of Adagloxad Simolenin (OBI 822)/OBI 821 Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients, defined as Residual Invasive Disease following Neoadjuvant Chemotherapy OR ≥4 Positive Axillary Nodes
TNBC adjuvant
6 Steering Committee
NeoTRIPaPDL1: Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin.
TNBC neoadjuvant
7 Steering Committee
Katherine: A randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with her2-positive primary breast cancer who have resudual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy
HER2+ adjuvant
8 Steering Committee
Kristine: A randomized, multicenter, open-label, five-arm, phase iii neoadjuvant study evaluating trastuzumab emtansine and pertuzumab alone or in combination with chemotherapy for patients with her2-positive breast cancer.
HER2+ neoadjuvant
9 Advisory board (for pharma investigating drug)
Boehringer Ingelheim - Afatinib (Giotrif® 妥復克)
10 Advisory board (for pharma investigating drug)
Amgen – Demosumab (Prolia® 保骼麗)
11 Advisory board (for pharma investigating drug)
Pfizer – Palbociclib (Ibrance® 愛乳適)
12 Advisory board (for pharma investigating drug)
Eli Lilly - Abemaciclib (Verzenio® 捷癌寧)
13 Advisory board (for pharma investigating drug)
OBI Pharma – Globo H 疫苗 (Trial: OPT-822-001)
14 Conduct clinical trials of new drugs and bring a New Drug to the Market
A randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with her2-positive primary breast cancer who have resudual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)
T-DM1(trastuzumab emtansine Kadcyla® 賀癌寧)
15 Conduct clinical trials of new drugs and bring a New Drug to the Market
A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy (HERA)
Trastuzumab Herceptin® 賀癌平
16 Conduct clinical trials of new drugs and bring a New Drug to the Market
A randomized, multicenter, open-label, five-arm, phase iii neoadjuvant study evaluating trastuzumab emtansine and pertuzumab alone or in combination with chemotherapy for patients with her2-positive breast cancer. (KRISTINE)